DOI: https://doi.org/10.30978/MG-2020-3-96

Доказова панкреатологія: що ми знаємо про хронічний панкреатит до 2020 року?

N. B. Gubergrits, N. V. Belyaeva, G. M. Lukashevich, K. N. Borodiy, P. G. Fomenko, E. V. Berezhnaya, V. S. Rakhmetova

Анотація


Висвітлено досягнення сучасної панкреатології в галузі патогенезу, динаміки розвитку та лікування хронічного панкреатиту (ХП). Розглянуто дані генетичних досліджень щодо генетичних мутацій, котрі призводять до виникнення ХП. Проаналізовано також генетичні мутації, які спричиняють розвиток раку підшлункової залози (ПЗ). Наведено чинники ризику розвитку автоімунного панкреатиту. Описано особ­ливості супутнього ураження нирок. Представлено концептуальну модель ХП, яка передбачає фазу раннього ХП. Наведено положення Міжнародного консенсусу про ранній ХП і діагностику цієї стадії ХП з використанням як клінічних/функціональних критеріїв, так і візуалізувальних методів досліджень. Розглянуто патофізіологічні особливості фіброгенезу в ПЗ. Проаналізовано результати досліджень особливостей виникнення зовнішньосекреторної недостатності ПЗ (ЗНПЗ), доцільність визначення фекальної еластази‑1 для скринінгу ЗНПЗ. Розглянуто особливості виникнення ЗНПЗ при остеопенії і кардіоваскулярних захворюваннях. Висвітлено нюанси проведення замісної ферментної терапії при стеатозі ПЗ, ожирінні, а також її вплив на якість і тривалість життя хворих на ХП із ЗНПЗ. Описано переваги застосування мінімікросфер в ентеросолюбільній оболонці та можливість купірування клінічних виявів ЗНПЗ, збільшення маси тіла, поліпшення якості життя та його тривалості при проведенні замісної ферментної терапії. Розглянуто оптимальні дози ферментних препаратів при призначенні замісної терапії. Наведено результати рандомізованих досліджень, які доводять ефективність мінімікросферичних препаратів.


Ключові слова


підшлункова залоза; хронічний панкреатит; зовнішньосекреторна недостатність підшлункової залози; діагностика; лікування

Повний текст:

PDF (Русский)

Посилання


Words of wisdom about medicine and healing: the sayings, aphorisms, quotes / Ed. Ya. S. Tsimmerman. Moscow: Geotar-Media, 2015:256.

Apte M, Pirola R, Wilson J. Pancreatic stellate cell: physiologic role, role in fibrosis and cancer. Curr Opin Gastroenterol. 2015;31:416-423. doi: 10.1097/MOG.0000000000000196

Bang UC, Benfield T, Hyldstrup L et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology. 2014;146(4):989-994. doi: 10.1053/j.gastro.2013.12.033

Barkin J, Barkin J. Chronic pancreatitis and bone disease. J Clin Densitom. 2019;S1094-6950 (19)30125-8. doi: 10.1016/j.jocd.2019.08.004

Birari R, Bhutani K. Pancreatic lipase inhibitors from natural sources: Unexplored potential. Drug Discov. 2007;12:879-889. doi: 10.1016/j.drudis.2007.07.024

Brennan GT, Saif MW. Pancreatic enzyme replacement therapy: a concise review. JOP. 2019;20(5):121-125.

Cohn JA, Friedman KJ, Noone PG et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med. 1998;339:653-658. doi: 10.1056/NEJM199809033391002

Czako L, Takacs T, Hegyi P et al. Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can J Gastroenterol. 2003;17 (10):597-603. doi: 10.1155/2003/515848

D’Haese JG, Ceyhan GO, Demir IE et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. Pancreas. 2014;43(6):834-841. doi: 10.1097/MPA.0000000000000131

De la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. J Clin Gastroenterol. 2018;52(8):e63-e72. doi: 10.1097/MCG.0000000000000917

De Martines D, Gianotten S, Wetzels J, van der Meijden W. Secondary hyperoxaluria due to pancreatic insufficiency. Netherl J Med. 2019;77(8):287-292.

Dominguez-Munoz J. Management of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2019;35(5):455-459. doi: 10.1097/MOG.0000000000000562

Felderbauer P, Hoffmann P, Einwachter H et al. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol. 2003;N. 3:34. doi: 10.1186/1471-230X-3-34

Fjeld K, Weiss FU, Lasher D et al. A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis. Nat Genet. 2015;47:518-522. doi: 10.1038/ng.3249

Frost F, Kacprowski T, Rühlemann M et al. Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity. Gastroenterology. 2019;156(4):1010-1015. doi: 10.1053/j.gastro.2018.10.047

Gómez J, Molero X, Vaquero E et al. Vitamin E attenuates biochemical and morphological features associated with development of chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G162-9. doi: 10.1152/ajpgi.00333.2003

Gubergrits N, Malecka-Panas E, Lehman GA et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther. 2011;33 (10):1152-1161. doi: 10.1111/j.1365-2036.2011.04631.× 18. Hohwieler M, Illing A, Hermann P et al. Human pluripotent stem cell derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut. 2017;66:473-486. doi: 10.1136/gutjnl-2016-312423

Huang W, Iglesia‑García D, Baston‑Rey I et al. Exocrine pancreatic insufficiency following acute pancreatitis: systematic review and meta‑analysis. Digestive Diseases and Sciences. 2019;64:1985-2005. doi: 10.1007/s10620-019-05568-9

Ito K, Matsuura K, Mihara Y et al. Delivery of pancreatic digestive enzymes into the gastrointestinal tract by pancreatic exocrine tissue transplant. Sci Rep. 2019;9. 5922. doi: 10.1038/s41598-019-42362-z

Ito T, Ishiguro H, Ohara H et al. Evidence based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol. 2016;51(2):85-92. doi: 10.1007/s00535-015-1149-× 22. Ito T, Kataoka K, Irisawa A et al. Prospective follow-up study of the patients with early CP or possible CP (The final report of the RCIPD chaired by Shimosegawa T). The RCIPD Report. 2015;145e9.

Kleeff J, Whitcomb DC, Shimosegawa T et al. Chronic pancreatitis. Nat Rev Dis Primers. 2017;3. 17060. doi: 10.1038/nrdp.2017.60

Kume K, Masamune A, Ariga H, Shimosegawa T. Alcohol consumption and the risk for developing pancreatitis: a case-control study in Japan. Pancreas. 2015;44:53-58. doi: 10.1097/MPA.0000000000000256

Kuno A, Yamada T, Masuda K et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003;124(4):1010-1019. doi: 10.1053/gast.2003.50147

Layer P, Kashirskaya N, Gubergrits N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World J Gastroenterol. 2019;25 (20):2430-2441. doi: 10.3748/wjg.v25.i20.2430

Lin Y, Tamakoshi A, Hayakawa T, Ogawa M, Ohno Y. Cigarette smoking as a risk factor for chronic pancreatitis: a case-control study in Japan. Research Committee on Intractable Pancreatic Diseases. Pancreas. 2000;21:109-114. doi: 10.1097/00006676-200008000-00001

Löhr JM, Domínguez-Muñoz E, Rosendahl J et al. United European Gastroenterology evidence based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterology Journal. 2017;5(2):153-199. doi: 10.1177/2050640616684695

Lowenfels A, Maisonneuve P, Cavallini G et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. Engl J Med. 1993;328:1433-1437. doi: 10.1056/NEJM199305203282001

Masamune A, Nakano E, Hamada S, Kakuta Y, Kume K, Shimosegawa T. Common variants at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with chronic pancreatitis in Japan. Gut. 2015;64:345-1346. doi: 10.1136/gutjnl-2015-309802

Masamune A, Nakano E, Kume K, Kakuta Y, Ariga H, Shimosegawa T. Identification of novel missense CTRC variants in Japanese patients with chronic pancreatitis. Gut. 2013;62:653-654. doi: 10.1136/gutjnl-2012-303860

Motoo Y. Antiproteases in the treatment of chronic pancreatitis. JOP. 2007;9(4):533-537.

Nagashio Y, Ueno H, Imamura M et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. Lab Invest. 2004;84 (12):1610-1618. doi: 10.1038/labinvest.3700191

Nikolic S, Dugic A, Steiner C et al. Chronic pancreatitis and the heart disease: Still terra incognita?. World J Gastroenterol. 2019;25 (44):6561-6570. doi: 10.3748/wjg.v25.i44.6561

Pei Y, Ai T, Deng Z et al. Impact of plant extract on the gastrointestinal fate of nutraceutical-loaded nano emulsions: Phytic acid inhibits lipid digestion but enhances curcumin bio accessibility. Food Funct. 2019;10:3344-3355. doi: 10.1039/c9fo00545e

Ramesh H, Reddy N, Bhatia S et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Pancreatology. 2013;13(2):133-139. doi: 10.1016/j.pan.2013.01.009

Reding T, Bimmler D, Perren A et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006;55(8):1165-1173. doi: 10.1136/gut.2005.077925

Ribichini E, Stigliano S, Rossi S et al. Role of fibre in nutritional management of pancreatic diseases. Nutrients. 2019;11. 2219. doi: 10.3390/nu11092219

Rosendahl J, Witt H, Szmola R et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet. 2008;40:78-82. doi: 10.1038/ng.2007.44

Safdi M, Bekal PK, Martin S et al. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas. 2006;33(2):156-162. doi: 10.1097/01.mpa.0000226884.32957.5e

Satouchi K, Matsushita S. Purification and properties of a lipase inhibiting protein from soy bean cotyledons. Agric Biol Chem. 1976;40:889-897. doi: 10.1271/bbb1961.40.889

Sharer N, Schwarz M, Malone G et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998;339:645-652. doi: 10.1056/NEJM199809033391001

Shimizu K, Shiratori K, Kobayashi M, Kawamata H. Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. Pancreas. 2004;29(1):67-74. doi: 10.1097/00006676-200407000-00058

Shimosegawa T. A new insight into chronic pancreatitis. Tohoku J Exp Med. 2019;248:225-238. doi: 10.1620/tjem.248.225

Shobassy M, Husainat N, Tabash A et al. Endoscopic ultrasound findings in patients diagnosed with exocrine pancreatic insufficiency by low fecal elastase-1. Gastroenterology Research and Practice. 2019:5. doi: 10.1155/2019/5290642

Singh G, Suresh S, Bayineni V, Kadeppagari R. Lipase inhibitors from plants and their medical applications. Int J Pharm Pharm Sci. 2015;7:1-5.

Szmola R, Sahin-Tóth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht’s enzyme Y. Proc Natl Acad Sci. 2007;104:11227-11232. doi: 10.1073/pnas.0703714104

Tahtaci M, Algın O, Karakan T et al. Can pancreatic steatosis affect exocrine functions of pancreas?. Turk J Gastroenterol. 2018;29:588-594. doi: 10.5152/tjg.2018.17696

The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery / Ed. By HG. Beger, A. L. Warshaw, R. H. Hruban et al. Oxford: Willey Blackwell, 2018:1173.

Thorat V, Reddy N, Bhatia S et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis — a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2012;36(5):426-436. doi: 10.1111/j.1365-2036.2012.05202.× 51. Toskes P et al. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas. 2011;40(3):376-382. doi: 10.1097/MPA.0b013e31820b971c

Ueda J, Tanaka M, Ohtsuka T et al. Research Committee of Intractable Diseases of the Pancreas. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. Surgery. 2013;153:357-364. doi: 10.1016/j.surg.2012.08.005

Vallejo-Senra N, de la Inglesia-Garcia D, Lopez-Lopez A et al. Cardiovascular risk (CVR) associated with pancreatic exocrine insufficiency (PEI) in patients with chronic pancreatitis (CP). 48th European Pancreatic Club (EPC) meeting. Pancreatology. 2016;16 (3S1):S80. doi: 10.1016/j.pan.2016.05.270

van Westerloo D, Florquin S, de Boer A et al. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol. 2005;166(3):721-728. doi: 10.1016/S0002-9440 (10)62293-6

Vujasinovic M, Hedström A, Maisonneuve P et al. Zinc deficiency in patients with chronic pancreatitis. World J Gastroenterol. 2019;25(5):600-607. doi: 10.3748/wjg.v25.i5.600

Vujasinovic M, Kunst G, Breznikar B et al. Is pancreatic exocrine insufficiency a cause of malabsorption in patients after bariatric surgery?. JOP. 2016;17:241-244.

Vujasinovic M, Pozzi Mucelli R, Valente R et al. Kidney Involvement in patients with type 1 autoimmune pancreatitis. J Clin Med. 2019;18(2):E258. doi: 10.3390/jcm8020258

Vujasinovic M, Valente R, Maier P et al. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatology. 2018;18(8):900-904. doi: 10.1016/j.pan.2018.09.003

Vujasinovic M, Valente R, Thorel A et al. Pancreatic exocrine insufficiency after bariatric surgery. Nutrients. 2017;9:1241. doi: 10.3390/nu9111241

Whitcomb DC, Frulloni L, Garg P et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16(2):218-224. doi: 10.1016/j.pan.2016.02.001

Whitcomb DC, Lehman GA, Vasileva G et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105 (10):2276-2286. doi: 10.1038/ajg.2010.201

Whitcomb DC, Shimosegawa T, Chari ST et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, Pancreas. Fest Working Group and European Pancreatic Club. Pancreatology. 2018;18:516-527. doi: 10.1016/j.pan.2018.05.008

Whitcomb DC, Gorry MC, Preston RA et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141-145. doi: 10.1038/ng1096-141

Whitcomb DC, LaRusch J, Krasinskas AM et al. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet. 2012;44:1349-1354. doi: 10.1038/ng.2466

Whitcomb DC, Preston RA, Aston CE et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology. 1996;110:1975-1980. doi: 10.1053/gast.1996.v110.pm8964426

Winny M, Paroglou V, Bektas H et al. Insulin dependence and pancreatic enzyme replacement therapy are independent prognostic factors for long-term survival after operation for chronic pancreatitis. Surgery. 2014;155(2):271-279. doi: 10.1016/j.surg.2013.08.012

Witt H, Beer S, Rosendahl J et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet. 2013;45:1216-1220. doi: 10.1038/ng.2730

Witt H, Luck W, Hennies HC et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000;25:213-216. doi: 10.1038/76088

Yamada T, Kuno A, Masuda K et al. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J Pharmacol Exp Ther. 2003;307(1):17-23. doi: 10.1124/jpet.103.053322

Zha M, Xu W, Jones P et al. Isolation and characterization of human islet stellate cells. Exp Cell Res. 2016;314:61-66. doi: 10.1016/j.yexcr.2015.11.002

Zhang Y, Cui L, Fang F. Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in rats X. 42nd European Pancreatic Club (EPC) meeting. Pancreatology. 2010;10:273. doi: 10.1097/MPA.0b013e3181744b50

Zheng Q, Koike K, Han L et al. New biologically active triterpenoid saponins from Scabiosa tschiliensis. J Nat Prod 2004;67:604-613. doi: 10.1021/np0304722

Zou WB, Boulling A, Masamune A et al. No association between CEL-HYB hybrid allele and chronic pancreatitis in Asian populations. Gastroenterology. 2016;150:1558-1560. doi: 10.1053/j.gastro.2016.02.071




© Сучасна гастроентерологія, 2020
© ТОВ «ВІТ-А-ПОЛ», 2020